Tessellate BIO’s Post

🚀 Exciting Clinical Milestone for Eisbach Bio! 🚀 We are thrilled to announce that the first patient has been dosed in our Phase 1/2 MATCH clinical trial of EIS-12656. The cancer trial conducted at The University of Texas MD Anderson Cancer Center, marks a significant step forward in our mission to develop transformative medicines leveraging synthetic lethality. “Our entry into the cancer clinic with the allosteric inhibitor EIS-12656 represents a unique approach in targeting ALC1, offering hope for patients with tumors characterized by impaired DNA damage and repair,” said Adrian Schomburg, Ph.D., Founder and CEO of Eisbach Bio GmbH. “This clinical study will explore EIS-12656’s potential to target specific genetic and molecular vulnerabilities, aiming to deliver a drug that is both efficacious and well-tolerated.” Full press release: https://lnkd.in/eTC65FeW Stay tuned for more updates as we continue our journey to pioneer the frontiers of cancer therapy. 💪 #CancerResearch #ClinicalTrials #Biotechnology #Oncology #SyntheticLethality

Exciting update! We've journeyed all the way from basic discovery to developing a promising drug candidate now in clinical trials. Our focus on disrupting a molecular machine involved in DNA repair could transform cancer therapy and bring new hope to many patients. Here's to advancing science and making a real impact! 🚀🔬 #CancerResearch #Innovation #ClinicalTrials

🔬 Exciting News in Cancer Research! 🔬 🌟 Firefly Bio: Revolutionizing Cancer Treatment 🌟 Firefly Bio, a cutting-edge biotech company, is making waves in the fight against cancer. They’ve developed a groundbreaking therapy called degrader-antibody conjugates (DACs), combining the best of antibody-drug conjugates (ADCs) with the power of protein degraders. Why DACs Matter? DACs promise to be more selective and potent in delivering their payload to cancer cells, while sparing healthy tissue. Plus, they can target new biology beyond the three mechanisms of action approved in ADCs. Funding and Dream Team Firefly Bio has secured a whopping $94 million in funding, with support from Eli Lilly and other investors. Their dream team includes experts from Versant Ventures, Genentech, Merck, Novartis, and even Nobel laureate Carolyn Bertozzi! Mission: Solid Tumors Firefly Bio’s mission? Tackling solid tumor targets that have faced dose-limiting toxicities. They’ve already selected a lead asset and proven their concept. #CancerResearch #FireflyBio #DACs #Innovation

The study titled "Mass Spectrometry Analysis of Glycopeptides Enriched by Anion Exchange-Mediated Methods Reveals PolyLacNAc-Extended N‑Glycans in Integrins and Tetraspanins in Melanoma Cells" by Čaval et al. investigates the role of glycopeptides in cancer progression. The researchers found that PolyLacNAc-extended N-glycans are present in integrins and tetraspanins in melanoma cells, providing valuable insights into the glycosylation patterns of these proteins. This discovery could have significant implications for understanding the mechanisms underlying melanoma progression and potentially lead to new therapeutic targets for the disease. This groundbreaking research highlights the power of mass spectrometry analysis in unraveling the complexities of glycoproteins and their role in cancer biology. By leveraging advanced analytical techniques, researchers can uncover novel glycosylation patterns that may have previously gone unnoticed, opening up new avenues for targeted therapies in melanoma and other cancers. Overall, this study represents a significant step forward in our understanding of glycoprotein biology and its implications for cancer research. To read the full article check the link: https://lnkd.in/dwUeTsSQ #MassSpectrometry #Glycoproteins #MelanomaResearch #CancerBiology #TherapeuticTargets

#biotechnology #cancertherapy #crispr #bioengineering ......................... The latest breakthrough in medical science is the CRISPR-based therapeutic targeting of signalling pathways in breast cancer. By utilizing this cutting-edge technology, medical professionals can precisely target and modify cancer cells at the molecular level, offering hope for more effective and less invasive treatments. With the potential to significantly improve patient outcomes, the CRISPR-based approach is a promising development in the fight against breast cancer.The involving complex signaling pathways in breast cancer such as P13K/AKT/mTOR, EPK/MAPK and Wnt/β catenin.Breast cancer is more likely to develop in people with mutations in BRCA1 and BRCA2 genes, PTEN (Cowden syndrome), p53 (Li-Fraumeni syndrome), STK11 (Peutz-Jeghers syndrome), and many other genes [11]. Mutations in cancer-suppressing genes like BRCA1 and BRCA2 are the most pivotal causes of familial breast cancer.There are innumerable anomalous genes that are responsible for the multi-factorial carcinogenesis pathway.

🔬 #Proteomics in #ClinicalOncology: Three weeks ago, we hosted an evening showcase in Paris – 'Next-Gen Proteomics for Advancing Translational and Clinical Oncology' at the Paris Saclay Cancer Cluster (PSCC). Today, we're happy to announce that the recordings are now available on our website. Don't miss out on Sandra Martínez Martín from Peptomyc discussing the "Biomarker Discovery Programme of OMO-103, a First-in-modality MYC Inhibitor". Despite the challenges associated with targeting the MYC oncoproteins, Omomyc has shown promising results in preclinical models, suggesting its potential therapeutic utility across various solid tumor types. One of the challenges of using therapeutic miniproteins is the development of a PK assay for accurate measurement of the drug within the patient tumor samples. In this presentation, Sandra explains how the de novo TrueSignature® LC-MS/MS proteomic assay was developed and characterized, targeting Omomyc and its use in normal routine of clinical trials for its accurate quantification in tumor biopsies. Join us to delve into the future of proteomics in oncology! 🌐👨🔬 👉 Watch the recording here: https://lnkd.in/eqSJG5By #Oncology #ClinicalResearch #DrugDiscovery #DrugDevelopment #Biomarkers

We will present preclinical proof-of-concept data for our proprietary lead programs, TUB-030 and TUB-040, targeting #SolidTumors at the upcoming American Association for Cancer Research’s Annual Meeting #AACR24. Our CSO, Jonas Helma-Smets, our CDO, Bjoern Hock, and our VP Biology & Translational Research, Annette Vogl, will be in San Diego, highlighting the preclinical differentiation of our ADC candidates in two poster presentations on April 8, 2024. Both candidates are characterized by disease-tailored composition and high stability, enabling an exceptionally wide therapeutic window. TUB-030 is directed against the #cancer antigen 5T4, expressed in a wide range of solid tumor indications. TUB-040 targets Napi2b, a well-characterized target in ovarian and lung cancer. Both candidates contain a topoisomerase-I-inhibitor as payload and are optimized for long-lasting, durable tumor engagement and minimal off-target toxicity. Find more details about the agenda and abstracts in the press release here: https://bit.ly/3SZ5Nq6 Stay tuned to learn more about the full preclinical data, which we will announce in a press release following the presentation at AACR.

Our CEO, Christian René Alexander Regenbrecht, and the Head of the Laboratory, Lena Wedeken, have arrived in San Diego to attend the AACR, which begins today. They will be presenting three posters showcasing our scientific work. „Mix and match - A comprehensive pipeline for matched patient-derived PDX and PD3D® modelsfor cancer research and preclinical drug development.“ Session: „Organoid Models of Cancer 1“ Session Date and Time: Sunday Apr 7, 1:30 PM - 5:00 PM Location: Poster Section 9 Poster Board Number: 24 „Turning data into information: Using PD3D® models to guide colorectal cancer therapy by Optim.AITM“ Session: Artificial Intelligence and Machine/Deep Learning 1 Session Date and Time: Sunday Apr 7, 1:30 PM - 5:00 PM Location: Poster Section 37 Poster Board Number: 6 „PD3D®models as jacks-of-all-trades for cancer research and therapy response prediction.“ Session „Organoid Models of Cancer 2“ Tuesday Apr 9, 9:00 AM - 12:30 PM Location: Poster Section 11 Poster Board Number: 6 If you like to meet Christian René Alexander Regenbrecht at AACR2024 in San Diego, feel free to schedule your appointment here:  https://lnkd.in/epHZWntW #AACR #AACR2024 #AACR24 #cancer #cancerresearch #science #cellphenomics #precisionmedicine #PD3D #organoids

You’re invited! Join us April 30 – May 2 for our virtual event highlighting the role of genomics tools in transforming oncology research. We’ll be hosting various activities, including: 💻Webinars: Improve FFPE and liquid biopsy processing and streamline viral-vector development for cancer therapeutics with our oncology-focused webinars 🗨️Live Discussions: Join industry experts for a live roundtable as they discuss improving Minimal Residual Disease (MRD) detection with cutting-edge NGS tools 🏆Grants: Enter to win one of four grants totaling $25,000 as we recognize excellence in oncology research. Together, we can advance oncology research and make a difference in the lives of those affected by cancer. Join the event: https://hubs.ly/Q02ryQ8f0 #Oncology #CancerResearch #Genomics #NGS #PrecisionMedicine

Last Sunday Maria Zeiler Alfsen presented a well attended poster about the development of a radioresistant PDX prostate cancer model to evaluate potential radiosensitizing compounds. Current models to study radioresistance in prostate cancer are based on cancer cell lines or cell-line derived xenograft models. These models do not account for the heterogenous and complex biology of the disease. We presented our work developing a PSMA-positive radioresistant patient-derived xenograft (PDX) prostate cancer model (ST1273, XenoSTART). Utilizing this radioresistant model we have investigated the treatment response of Lu177-PSMA-617 in combination with different drug inhibitor classes to evaluate their potential radiosensitizing effect. Meet us today at booth #4450 to explore how molecular imaging can enhance your translational cancer research programs. Click here to learn more about the poster: https://lnkd.in/eZkWz-WE   #AACR24 #oncology #PDX #PSMA #radiopharmaceuticals #molecularimaging #diagnostics #theranostics